| Literature DB >> 36017350 |
Genglei Chu1, Weidong Zhang2, Feng Han1, Kexin Li1, Chengyuan Liu1, Qiang Wei1, Huan Wang1, Yijie Liu1, Fengxuan Han1, Bin Li1,3.
Abstract
Regenerative medicine for intervertebral disc (IVD) disease, by utilizing chondrocytes, IVD cells, and stem cells, has progressed to clinical trials in the treatment of back pain, and has been studied in various animal models of disc degeneration in the past decade. Stem cells exist in their natural microenvironment, which provides vital dynamic physical and chemical signals for their survival, proliferation and function. Long-term survival, function and fate of mesenchymal stem cells (MSCs) depend on the microenvironment in which they are transplanted. However, the transplanted MSCs and the endogenous disc cells were influenced by the complicated microenvironment in the degenerating disc with the changes of biochemical and biophysical components. It is important to understand how the MSCs and endogenous disc cells survive and thrive in the harsh microenvironment of the degenerative disc. Furthermore, materials containing stem cells and their natural microenvironment have good clinical effects. However, the implantation of tissue engineering IVD (TE-IVD) cannot provide a complete and dynamic microenvironment for MSCs. IVD graft substitutes may need further improvement to provide the best engineered MSC microenvironment. Additionally, the IVD progenitor cells inside the stem cell niches have been regarded as popular graft cells for IVD regeneration. However, it is still unclear whether actual IVD progenitor cells exist in degenerative spinal conditions. Therefore, the purpose of this review is fourfold: to discuss the presence of endogenous stem cells; to review and summarize the effects of the microenvironment in biological characteristics of MSC, especially those from IVD; to explore the feasibility and prospects of IVD graft substitutes and to elaborate state of the art in the use of MSC transplantation for IVD degeneration in vivo as well as their clinical application.Entities:
Keywords: intervertebral disc; microenvironment; regenerative medicine; stem cell; tissue regeneration
Year: 2022 PMID: 36017350 PMCID: PMC9395990 DOI: 10.3389/fbioe.2022.968862
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Tissue-specific progenitor cells and the location of stem cell niche. The IVD is the fibrocartilaginous part of a three three-component construct that consists of the nucleus pulposus (NP) in the center and annulus fibrosus (AF) in the surrounding, both of which are connected by cartilaginous endplates (CE). Progenitor cells have been found in all three constructs, respectively, referred to NPSCs, AFSCs, and CESCs. The perichondrium region adjacent to the epiphyseal plate and the AF border to the ligament zone has been suggested to be the IVD stem cell niche.
Surface markers of IVD progenitor cells.
| Species | Cell type | Surface markers | Ref |
|---|---|---|---|
| Human | CESC | CD14−, CD19−, CD34−, CD45−, HLA-DR-, CD44+, CD73+, CD90+, CD105+, CD133+, CD166+, Stro-1+ |
|
| Human | CESC | HLA-DR-, CD14−, CD19−, CD34−, CD45−, CD73+, CD90+, CD105+ |
|
| Human | AFSC, NPSC | CD34−, CD49a+, CD63+, CD73+, CD90+, CD105+, CD166+, p75 NTR+, CD133/1+ |
|
| Human | IVDSC | CD90+, CD105+, Stro-1+ |
|
| Rhesus macaque | NPSC | CD90−, CD45−, CD44+, CD90+, CD146+, CD166+, HLA-DR+ | Huang et al. (2013a) |
| Human | NPSC | CD29−, CD45−, CD24+, CD73+, CD90+, CD105+ |
|
| Rat | NPSC | CD34−, CD45−, CD44+, CD90+, CD105+ |
|
| Human | NPSC | CD29−, CD44−, CD73−, CD90−, CD105-, CD29+, CD44+, CD73+, CD90+, CD105+ |
|
| Human | NPSC | CD34−, CD45−, CD73+, CD90+, CD105+ |
|
| Human | NPSC | HLA-DR-, CD34−, CD45−, CD73+, CD90+, CD105+ |
|
FIGURE 2IVD microenvironment changes and IVD progenitor cells in healthy and degenerated IVD. The microenvironment of the degenerated IVD is characterized by metabolic disorders, acidic, inflammatory, poor nutrient supply, and low oxygen level, which offer a hostile microenvironment for IVD progenitor cells. Degenerative disc disease can lead to decreased differentiation potency, survival, chemotaxis, and proliferation of the IVD progenitor cells, the hostile microenvironment in the IVD might be unfavorable to the activity of progenitor cell.
FIGURE 3Effects of different modes of mechanical loading on the influence of IVD in vivo. (A) Gross observation of rat tail IVDs in the sham group, compression group, release group and traction group. (B) Magnetic resonance images (MRI) of IVDs from the groups as described above. (C) H&E staining of IVDs from the groups as described above. Reproduced with permission from Zhang et al. (Zhang W. et al., 2021).
FIGURE 4Combined effects of substrate topography and stiffness on the influence of AFSC differentiation. (A) Assembly of electrospun fibrous membranes with different fiber size and stiffness led to specifically differentiated AFSCs that mimic the hierarchical stratified structure of native AF tissue. Reproduced with permission from Zhou et al. (Zhou et al., 2021). (B) The morphology and YAP expression of AFSCs on scaffolds. (C) Expression of AF phenotypic marker genes cultured on electrospun fibrous membranes scaffolds for 7 days. Reproduced with permission from Chu et al. (Chu G. et al., 2019).
Clinical studies utilizing cell-based therapies to treat chronic low back pain.
| Author, year | Clinical details | Cells transplanted | Results |
|---|---|---|---|
|
| 10 patients with low back pain and evidence of DDD | Autologous MSCs | Clinical improvement in back pain, leg pain and disability. Disc height not recovered. Increased MRI T2 signal |
|
| 2 patients with back pain and sciatica, with radiological evidence of DDD and lumbar canal stenosis | Autologous marrow MSCs | Clinical improvement in both patients. Increased MRI T2 signal. Less instability |
|
| 4 patients undergo MSC injection and who later opted for spinal surgery | autologous MSCs | The labelled MSCs have differentiated into chondrocyte-like cells and were distributed at different parts of the IVD |
|
| 33 patients with lower back pain and disc bulge | Autologous BM-MSCs | Mean 60% Clinical improvement in all patients. MRI showed a reduction in disc bulge. Patients with greater bulge reduction reported less pain |
|
| 10 patients with low back pain due to DDD | Autologous AT-MSCs | No statistical difference between high and low dose arms. 1 Patient with improved Pfirmann grade. Greater than 50% (Oswestry Disability Index) ODI and (visual analog scale) VAS in 13 patients |
|
| 5 patients with back pain and sciatica | Autologous hypoxic-cultured BM-MSCs | A positive association between clinical improvement and stem cell therapies. MRI showed reduced disc protrusion |
|
| 24 patients with low back pain | Allogenic BM-MSCs | MRI showed improvement in MSC patients VS. disc degeneration in controls. Stem cell patients had significant ODI VAS and ODI VAS reductions at 3, 6, 12 months. MRI showed disc degeneration in controls VS. improvement in MSC patients |
|
| 28 patients undergoing microdiscectomy with back pain | Autologous culture expanded disc derived chondrocytes | Patients receiving cell transplantation had reduced back pain at 2 years. Increased MRI T2 signal of treated and adjacent discs |